Oriol Sibila Vidal

List of Publications by Year
in descending order

128 papers	4,692 citations	145106 33 h-index	129628 63 g-index
134 all docs	134 docs citations	134 times ranked	6621 citing authors

#	Article	IF	Citations
1	Estudio de la enfermedad pulmonar intersticial difusa mediante el anÃ¡lisis de partÃculas volÃ¡tiles en el aire exhalado. Archivos De Bronconeumologia, 2022, 58, 99-101.	0.4	1
2	SARSâ€CoVâ€2 pneumonia and atypical lymphocyte morphology in pleural fluid. International Journal of Laboratory Hematology, 2022, 44, .	0.7	1
3	Atypical lymphoid cells circulating in blood in COVID-19 infection: morphology, immunophenotype and prognosis value. Journal of Clinical Pathology, 2022, 75, 104-111.	1.0	14
4	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	3.1	21
5	Breath analysis using electronic nose and gas chromatography-mass spectrometry: A pilot study on bronchial infections in bronchiectasis. Clinica Chimica Acta, 2022, 526, 6-13.	0.5	6
6	Biomarcadores biolÃ³gicos en las enfermedades respiratorias. Archivos De Bronconeumologia, 2022, 58, 323-333.	0.4	14
7	[Translated article] Study of diffuse interstitial lung disease with the analysis of volatile particles in exhaled air. Archivos De Bronconeumologia, 2022, 58, T99-T101.	0.4	2
8	Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study. Biomedicines, 2022, 10, 225.	1.4	4
9	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	2.5	67
10	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. European Respiratory Journal, 2022, 59, 2103036.	3.1	9
11	Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose. Archivos De Bronconeumologia, 2022, 58, 663-665.	0.4	1
12	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. Respiratory Research, 2022, 23, 37.	1.4	23
13	[Translated article] Biological Biomarkers in Respiratory Diseases. Archivos De Bronconeumologia, 2022, 58, T323-T333.	0.4	11
14	Future Directions in Bronchiectasis Research. Clinics in Chest Medicine, 2022, 43, 179-187.	0.8	7
15	[Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia. Archivos De Bronconeumologia, 2022, 58, T444-T447.	0.4	0
16	Blood Neutrophil Counts Define Specific Clusters of Bronchiectasis Patients: A Hint to Differential Clinical Phenotypes. Biomedicines, 2022, 10, 1044.	1.4	7
17	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2021, 159, 58-72.	0.4	24
18	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	3.0	23

#	Article	IF	Citations
19	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. Chest, 2021, 159, 1758-1767.	0.4	18
20	Low birth weight as a potential risk factor for severe COVID-19 in adults. Scientific Reports, 2021, 11, 2909.	1.6	10
21	Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. Archivos De Bronconeumologia, 2021, 57, 59-61.	0.4	36
22	Proteaseâ€“Antiprotease Imbalance in Bronchiectasis. International Journal of Molecular Sciences, 2021, 22, 5996.	1.8	17
23	Long-Term Antibiotics in Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 606-615.	0.8	0
24	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. Biomedicines, 2021, 9, 905.	1.4	5
25	Role of respiratory intermediate care units during the SARS-CoV-2 pandemic. BMC Pulmonary Medicine, 2021, 21, 228.	0.8	12
26	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. International Journal of Environmental Research and Public Health, 2021, 18, 8431.	1.2	21
27	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine,the, 2021, 9, 873-884.	5.2	99
28	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Archivos De Bronconeumologia, 2021, 57, 21-27.	0.4	30
29	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
30	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Archivos De Bronconeumologia, 2021, 57, 21-27.	0.4	35
31	Reducing Pseudomonas sputum density in bronchiectasis. European Respiratory Journal, 2021, 57, 2003390.	3.1	3
32	Study of diffuse interstitial lung disease with the analysis of volatile particles in exhaled air. Archivos De Bronconeumologia, 2021, , .	0.4	0
33	Early hospital readmission increases short and long - term mortality in patients with interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021021.	0.2	0
34	COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. Chest, 2020, 157, 824-833.	0.4	16
35	Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551.	1.3	31
36	Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 639-640.	2.5	4

#	Article	IF	Citations
37	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 2020, 383, 2127-2137.	13.9	158
38	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525.	1.3	18
39	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. European Respiratory Journal, 2020, 56, 2001702.	3.1	15
40	Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respiratory Medicine,the, 2020, 8, 436-438.	5.2	314
41	Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. European Respiratory Journal, 2020, 56, 2000608.	3.1	22
42	Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity. Respiratory Research, 2020, 21, 21.	1.4	9
43	InflamaciÃ³n local y sistÃ©mica en bronquiectasias. Endotipos y biomarcadores. Open Respiratory Archives, 2020, 2, 235-241.	0.0	0
44	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	2.9	116
45	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	2.7	43
46	Response to: Comment on â€œNoninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Studyâ€. Canadian Respiratory Journal, 2019, 2019, 1-2.	0.8	0
47	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. Journal of Clinical Medicine, 2019, 8, 1461.	1.0	7
48	Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. BMC Pulmonary Medicine, 2019, 19, 112.	0.8	28
49	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and riskÂofÂexacerbation. European Respiratory Journal, 2019, 53, 1900303.	3.1	50
50	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 33-41.	2.5	70
51	Noninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Study. Canadian Respiratory Journal, 2019, 2019, 1-10.	0.8	2
52	Biomarkers in community-acquired pneumonia: still searching for the one. European Respiratory Journal, 2019, 53, 1802469.	3.1	11
53	Effects of a polysaccharide-based multi-ingredient supplement on salivary immunity in non-elite marathon runners. Journal of the International Society of Sports Nutrition, 2019, 16, 14.	1.7	5
54	An international perspective on hospitalized patients with viral community-acquired pneumonia. European Journal of Internal Medicine, 2019, 60, 54-70.	1.0	26

#	Article	IF	Citations
55	Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respiratory Medicine, 2018, 136, 111-117.	1.3	21
56	Pathophysiology, Immunology, and Histopathology of Bronchiectasis. , 2018, , 51-64.		2
57	Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 117-127.	1.5	207
58	Salivary immunity and lower respiratory tract infections in non-elite marathon runners. PLoS ONE, 2018, 13, e0206059.	1.1	16
59	Treatable traits in bronchiectasis. European Respiratory Journal, 2018, 52, 1801269.	3.1	84
60	<i>Pseudomonas aeruginosa</i> in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study. Respiration, 2018, 96, 417-424.	1.2	45
61	Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. European Respiratory Journal, 2018, 52, 1701190.	3.1	122
62	Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2018, 81, 187.	0.7	70
63	Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. Respiration, 2018, 96, 406-416.	1.2	22
64	Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach?. PeerJ, 2018, 6, e4211.	0.9	8
65	New biomarkers in communityâ€acquired pneumonia: <scp>A</scp>nother step in improving outcome prediction. Respirology, 2017, 22, 416-417.	1.3	4
66	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
67	Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. Respiratory Medicine, 2017, 128, 1-6.	1.3	18
68	Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1384-1393.	2.5	232
69	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 609-620.	2.5	120
70	The respiratory threat posed by multidrug resistant <scp>G</scp>ramâ€negative bacteria. Respirology, 2017, 22, 1288-1299.	1.3	84
71	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	3.1	9
72	Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood. Journal of Asthma and Allergy, 2017, Volume10, 269-276.	1.5	8

#	Article	IF	Citations
73	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE, 2017, 12, e0178022.	1.1	25
74	Relationship Between Severity Classification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Clinical Outcomes in Hospitalized Patients. Cureus, 2017, 9, e988.	0.2	3
75	<scp>Pseudomonas aeruginosa</scp> resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology, 2016, 21, 1235-1242.	1.3	33
76	Reply: Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 2104-2105.	1.5	1
77	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 913-922.	0.8	10
78	Diagnostic challenges of bronchiectasis. Respiratory Medicine, 2016, 116, 70-77.	1.3	27
79	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. Chest, 2016, 150, 123-130.	0.4	50
80	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	1.4	54
81	Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376.	4.6	109
82	Multidrug-resistant pathogens in patients with pneumonia coming from the community. Current Opinion in Pulmonary Medicine, 2016, 22, 219-226.	1.2	29
83	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 636-642.	1.5	19
84	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. PLoS ONE, 2015, 10, e0135199.	1.1	62
85	Risk factors and antibiotic therapy in <scp>P</scp>.â€‰aeruginosa communityâ€acquired pneumonia. Respirology, 2015, 20, 660-666.	1.3	34
86	Secreted mucins and airway bacterial colonization in nonâ€<scp>CF</scp> bronchiectasis. Respirology, 2015, 20, 1082-1088.	1.3	43
87	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 391-401.	2.5	61
88	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. JAMA - Journal of the American Medical Association, 2015, 313, 677.	3.8	428
89	Migratory Pulmonary Nodules in a Patient With Ulcerative Colitis. Archivos De Bronconeumologia, 2015, 51, 303-304.	0.4	2
90	NÃ³dulos pulmonares migratorios en paciente con colitis ulcerosa. Archivos De Bronconeumologia, 2015, 51, 303-304.	0.4	2

#	Article	IF	Citations
91	The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulmonary Pharmacology and Therapeutics, 2015, 32, 130-136.	1.1	18
92	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	0.9	8
93	Impact of Macrolide Therapy in Patients Hospitalized With Pseudomonas aeruginosa Community-Acquired Pneumonia. Chest, 2014, 145, 1114-1120.	0.4	16
94	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respiratory Research, 2014, 15, 75.	1.4	24
95	Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. European Respiratory Journal, 2014, 43, 36-42.	3.1	28
96	Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. Respiratory Medicine, 2014, 108, 1608-1614.	1.3	55
97	Procalcitonin Does Not Decrease Antibiotic Duration in an Antimicrobial Stewardship Driven MICU. Chest, 2014, 146, 215A.	0.4	0
98	Hospitalized AECOPD Patients Not Treated With Antibiotic Have Higher Rates of 1-Year Pneumonia Related Hospitalization. Chest, 2014, 146, 65A.	0.4	0
99	Antiplatelets Improve Survival Among Critically Ill Mechanically Ventilated Patients. Chest, 2014, 146, 500A.	0.4	1
100	Clinical Efficacy of Azithromycin in Patients With Severe Sepsis: Open Label Pilot Randomized Controlled Trial. Chest, 2014, 145, 151A.	0.4	0
101	Severity assessment tools in CAP. , 2014, , 88-104.		3
102	Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. Journal of Critical Care, 2013, 28, 284-290.	1.0	18
103	What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the) Tj ETQq1 1 0.784314 rgBT /Ove North America, 2013, 27, 133-147.	1.9	20
104	Corticosteroids for pneumonia: Are we there yet?. Respirology, 2013, 18, 199-200.	1.3	1
105	The Paradoxical Effect on Pneumonia of Chronic Inhaled Corticosteroids. Clinical Pulmonary Medicine, 2013, 20, 6-10.	0.3	8
106	Effects of Inhaled Corticosteroids on Pneumonia Severity and Antimicrobial Resistance. Respiratory Care, 2013, 58, 1489-1494.	0.8	11
107	Monotherapy vs Combination Antibiotic Therapy for Patients Admitted for Pseudomonas Community-Acquired Pneumonia. Chest, 2013, 144, 389A.	0.4	0
108	Chronic bronchitis: a risk factor for bronchial infection. , 2013, , 18-26.		0

#	Article	IF	Citations
109	Evaluation of the IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia. Hospital Practice (1995), 2012, 40, 158-164.	0.5	6
110	Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2012, 142, 1193-1199.	0.4	56
111	Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia. Therapeutic Advances in Respiratory Disease, 2012, 6, 323-330.	1.0	2
112	Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers. Expert Review of Clinical Pharmacology, 2012, 5, 445-458.	1.3	16
113	Nocardiosis pulmonar en pacientes con EPOC: caracterÃsticas y factores pronÃ³sticos. Archivos De Bronconeumologia, 2012, 48, 280-285.	0.4	26
114	Immunological Response to Mycoplasma pneumoniae (Mp) and CARDS Toxin Is Related to Severe Histological Inflammation and a TH2 Response in a Primate Model. Chest, 2012, 142, 192A.	0.4	0
115	Improving Appropriate Utilization of Procalcitonin in Critically Ill Medical Patients. Chest, 2012, 142, 364A.	0.4	0
116	Corticoides en la neumonÃa: argumentos a favor. Archivos De Bronconeumologia, 2011, 47, 222-223.	0.4	0
117	An experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated piglets. European Respiratory Journal, 2010, 36, 901-906.	3.1	16
118	Animal models of ventilator-associated pneumonia. European Respiratory Journal, 2009, 33, 182-188.	3.1	47
119	Optimal Positive Endâ€Expiratory Pressure During Pumpless Extracorporeal Lung Membrane Support. Artificial Organs, 2008, 32, 885-890.	1.0	8
120	Effects of glucocorticoids in ventilated piglets with severe pneumonia. European Respiratory Journal, 2008, 32, 1037-1046.	3.1	59
121	Corticosteroids in severe pneumonia. European Respiratory Journal, 2008, 32, 259-264.	3.1	49
122	Corticoids in Severe Pneumonia. , 2008, , 45-51.		0
123	Experimental Severe Pseudomonas aeruginosa Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation. Chest, 2007, 132, 523-531.	0.4	41
124	Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response. European Respiratory Journal, 2007, 30, 1167-1172.	3.1	28
125	Experimental safety and efficacy evaluation of an extracorporeal pumpless artificial lung in providing respiratory support through the axillary vessels. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 339-345.e2.	0.4	16
126	Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Current Opinion in Infectious Diseases, 2006, 19, 179-184.	1.3	11

#	Article	IF	Citations
127	Pulmonary infections in non-HIV-immunocompromised patients. Current Opinion in Pulmonary Medicine, 2005, 11, 213-217.	1.2	27
128	Nosocomial pneumonia in immunosuppressed patients1. Infectious Disease Clinics of North America, 2003, 17, 785-800.	1.9	8